On May 29, Bio Medica Laboratories' shares made their debut on the NSE SME platform, listing at a 20% discount to the issue price. This discount suggests that investor interest was lower than anticipated. The company has stated that it intends to utilize the funds raised through the IPO primarily for repaying existing loans and expanding its manufacturing facilities. Following the initial listing, the shares extended their decline to hit the 5% lower price band. This development highlights the cautious sentiment among investors towards the company's public offering in the current market environment. Bio Medica Laboratories saw its shares debut at a 20% discount on May 29, reflecting lower-than-expected investor interest.